Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Incyte logo

Incyte

Status and phase

Withdrawn
Phase 3

Conditions

Head and Neck Cancer

Treatments

Drug: Cetuximab
Drug: Placebo
Drug: Epacadostat
Drug: Cisplatin
Drug: Carboplatin
Drug: Nivolumab
Drug: 5-Fluorouracil

Study type

Interventional

Funder types

Industry

Identifiers

NCT03342352
CA2099NA/ECHO-310

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and efficacy of the combination of nivolumab plus epacadostat in combination with chemotherapy in first-line recurrent or metastatic patients with squamous cell carcinoma of the head and neck (SCCHN) when compared to the standard of care (EXTREME regimen).

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Histologically confirmed SCCHN from any of the following primary sites: oral cavity, oropharynx, hypopharynx, and larynx.
  • Must have recurrent or metastatic disease that is not amenable to therapy with curative intent (surgery and/or radiation therapy with or without chemotherapy).
  • No prior treatment with systemic anti-cancer therapy for SCCHN unless protocol-defined conditions are met.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to1.
  • Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1.
  • Documentation of program death ligand-1 (PD-L1) status prior to randomization.

Exclusion criteria

  • Recurrent or metastatic carcinoma of the nasopharynx and paranasal sinuses, squamous cell carcinoma that originated from the skin and salivary gland or non-squamous histologies (e.g., mucosal melanoma) and SCCHN of unknown primary origin.
  • Untreated central nervous system (CNS) metastases.
  • Carcinomatous meningitis.
  • Active, known or suspected autoimmune disease.
  • Physical and laboratory test findings outside the protocol-defined range.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

0 participants in 3 patient groups

Arm A
Experimental group
Description:
Nivolumab plus epacadostat in combination with platinum (carboplatin/cisplatin) plus 5-fluorouracil.
Treatment:
Drug: 5-Fluorouracil
Drug: Nivolumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Epacadostat
Arm B
Active Comparator group
Description:
EXTREME regimen.
Treatment:
Drug: 5-Fluorouracil
Drug: Carboplatin
Drug: Cisplatin
Drug: Cetuximab
Arm C
Experimental group
Description:
Nivolumab plus placebo for epacadostat in combination with platinum (carboplatin/cisplatin) plus 5-fluorouracil.
Treatment:
Drug: 5-Fluorouracil
Drug: Nivolumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems